Immunotherapy Also Found Effective in Prostate Cancer and May Stop This Tumor’s Metastasis

Immunotherapies offer an effective treatment opportunity by enabling the immune system to recognize cancer cells. Until now, apart from the FDA -approved Spliuecel T dendritic cell vaccine, no study had shown that immunotherapies increased survival in prostate cancer. ASCO 2018 featured research showing, for the first time, that an immune checkpoint inhibitor benefited patients with prostate cancer.
- Related topic: How does the Sipuleucel-T (Provenge) prostate cancer vaccine work, and which patients is it suitable for?
The study was conducted at the Institute of Cancer Research in London in 258 prostate cancer patients resistant to both docetaxel chemotherapy and castration (hormone suppression). Clinical trial participants received pembrolizumab (Keytruda), an immune checkpoint inhibitor targeting PD-1.
The study found:
- Prostate cancer patients treated with pembrolizumab were observed to have longer survival.
- In this patient group resistant to existing treatments, 38% were still alive after 1 year. In 11%, no tumor progression or growth was observed.
- PD-L1 positivity or negativity did not significantly affect the response to pembrolizumab.
- In 5% of patients, the tumor shrank almost completely or disappeared after treatment. In these patients, DNA repair genes contained a mutation . According to the researchers, cancer cells with this type of mutation are more easily destroyed by the immune system.
What does this study tell us?
- This research shows benefit in prostate cancer from the new-generation immunotherapies known as immune checkpoint inhibitors; it is the first study of its kind.
- In solid (organ-based) tumors such as prostate cancer, immunotherapies cannot benefit nearly half of patients. This is because of the presence in the tumor microenvironment of cells that suppress the immune system. In this study, examining the genetic profiles of patients who responded to the drug may identify biomarkers . This could make it possible to predict which patients will benefit from immunotherapies.
- Immunotherapies are thought likely to benefit patients with mutations in DNA repair genes. Therefore, combining checkpoint inhibitors with DNA repair protein inhibitors may be an effective treatment strategy. Further clinical trials are needed to confirm this.
Related Topics:
- More than 40% of prostate biopsies could be avoided with a new blood test
- Which treatment should be chosen for newly diagnosed stage 4 prostate cancer?
Sources
KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
2018 ASCO Annual Meeting - J Clin Oncol 36, 2018 (suppl; abstr 5007)
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.